RPRX News and Press, Royalty Pharma plc

2024-06-26 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’m on the hunt for ‘Strong Buy’ biotech stocks . According to Finviz.com, there are 680 U.S.-listed biotech stocks. Of those, 73 have a market capitalization o...

2024-06-24 12:56:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, in...

2024-06-12 07:41:46 ET Summary Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itse...

2024-06-08 06:50:00 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2024-06-05 06:14:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of r...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pha...

2024-06-03 17:21:16 ET More on Royalty Pharma Royalty Pharma: Solid Start Of The Year, Buy Confirmed Agios in pact with Royalty Pharma for brain tumor candidate Cytokinetics to get up to $575M in funding from Royalty Pharma Seeking Alpha’s Quant Rating...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $500 million of 5.150% Notes due 2029 (the “...

2024-06-03 10:15:02 ET UBS analyst issues NEUTRAL recommendation for RPRX on June 3, 2024 08:53AM ET. The previous analyst recommendation was Buy. RPRX was trading at $27.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...

2024-06-03 10:00:06 ET Ashwani Verma from UBS issued a price target of $28.00 for RPRX on 2024-06-03 08:53:00. The adjusted price target was set to $28.00. At the time of the announcement, RPRX was trading at $27.35. The overall price target consensus is at $49.00 with h...